Key Drivers
- Very high margins
- Negative free cashflow
- Negative equity
AIAI Summary
Novavax has effectively become a royalty- and milestone-dependent platform where upside now hinges on partner-triggered payments (Sanofi/Pfizer/Matrix‑M licenses) rather than product sales, so investors should model milestone probabilities, monitor partner commercialization signals closely, and treat current accounting profits cautiously given negative cash conversion and deferred‑revenue obligations.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Very high margins
- •Negative free cashflow
- •Negative equity
Novavax posts strong FY2025 profitability and low valuation multiples but is offset by negative shareholders' equity, persistent negative free cash flow, large deferred revenue, and quarter-to-quarter margin volatility.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Short-term support
- •Failed reclaim
NVAX has shown modest resilience last month (+~4%) but lost short-term momentum after a late‑Feb peak (~$11.19) and is pulling back toward $9.2–9.5, with a break below ~$9.20 likely signaling further weakness.
~14% drop from the ~ $11.19 late‑Feb peak into mid‑March indicating increased downside risk
Sentiment & News
Key News Insights:
- •Royalty-driven shift
- •Sanofi milestone
- •Volatile investor flows
Novavax moved to a royalty-driven, partner-dependent business mix after Q4/2025 results and Sanofi/Pfizer milestones drove surprise profits, sharp share gains and mixed investor flows.
The company's fundamentals improved via milestone cash but dependence on partner outcomes makes the stock event-driven and likely to remain volatile
Similar Companies in Healthcare
Other companies in the same sector with AI ratings